Jefferies initiates Acuren stock with Buy rating on margin expansion outlook

Jefferies initiated coverage on Acuren Corp. (NYSE:TIC) with a Buy rating and a $16.00 price target, projecting a 51% upside based on expectations for 200 basis points of EBITDA margin expansion to 18% by 2027. This anticipated improvement is driven by cost synergies from the recently acquired NV5 and strategic operational enhancements, with Jefferies viewing the $20 million synergy target as conservative. The initiation follows Acuren's Q2 2025 results, which showed a 1.5% service revenue increase but a decline in adjusted EBITDA and margins to 17.4%, highlighting the market's focus on the NV5 integration's impact on future profitability.

Analysis

Jefferies has initiated coverage on Acuren Corp. (TIC) with a Buy rating and a $16.00 price target, signaling a potential 51% upside. The core of this bullish thesis rests on significant EBITDA margin expansion, projected to grow by 200 basis points to 18% by 2027, with a long-term target exceeding 20%. This optimism is primarily fueled by the anticipated benefits of the recent $1.7 billion acquisition of NV5, with Jefferies viewing the company's $20 million cost synergy target as conservative. However, this forward-looking projection stands in contrast to Acuren's latest financial results. The company's Q2 2025 report, while showing a modest 1.5% year-over-year increase in service revenue to $313.9 million, revealed a decline in adjusted EBITDA to $54.6 million from $59.1 million in the prior year. Consequently, the EBITDA margin contracted from 19.1% to 17.4%. This performance highlights a critical juncture for the company, where the successful integration of NV5 and the realization of projected synergies must reverse the current trend of margin compression to justify its relatively high 34x EV/EBITDA multiple.

Key Decisions for Investors

• Investors aligned with Jefferies' M&A synergy thesis may consider the current price an attractive entry point, given the projected 51% upside and long-term margin expansion narrative.
• It is critical to scrutinize upcoming quarterly earnings for tangible evidence of cost synergies and a reversal of the recent EBITDA margin decline to 17.4%, as the high 34x EV/EBITDA valuation creates significant downside risk if integration falters.
• Consider the investment as a play on execution, weighing the potential rewards of a successful NV5 integration against the demonstrated operational headwind of declining profitability in the most recent quarter.